title: Administration of Triton WR 1339 aggravates chronic aminonucleoside nephrosis.
authors.forename: K
authors.initials: K
authors.lastname: Obara
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Shoji
authors.forename: S
authors.initials: S
authors.lastname: Chiba
authors.forename: J
authors.initials: J
authors.lastname: Soma
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Yoshinaga
mesh_terms: D000818:Animals; D002784:Cholesterol / Q000097:blood; D002908:Chronic Disease; D004195:Disease Models, Animal; D004357:Drug Synergism; D006949:Hyperlipidemias; D007275:Injections, Intravenous; D050356:Lipid Metabolism; D008297:Male; D009401:Nephrosis / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects; D011692:Puromycin Aminonucleoside / Q000008:administration & dosage / Q000009:adverse effects*; D051381:Rats; D011919:Rats, Inbred Strains; D014280:Triglycerides / Q000097:blood
chemical_list: D014280:Triglycerides; D011092:Polyethylene Glycols; D011692:Puromycin Aminonucleoside; D002784:Cholesterol; C016811:tyloxapol